Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. 10x Genomics, Inc.
  6. Summary
    TXG   US88025U1097

10X GENOMICS, INC.

(TXG)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-01 pm EST
47.59 USD   +1.62%
01/1910x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
PR
01/09Transcript : 10x Genomics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-08-2023 through Jan-12-2023
CI
01/05Cornell University : Method precisely locates gene activity and proteins across tissues
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2023 01/27/2023 01/30/2023 01/31/2023 02/01/2023 Date
48.03(c) 48.65(c) 45.37(c) 46.83(c) 47.59(c) Last
880 394 696 676 909 500 623 477 824 527 Volume
+4.41% +1.29% -6.74% +3.22% +1.62% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 508 M - -
Net income 2022 -184 M - -
Net cash position 2022 200 M - -
P/E ratio 2022 -29,2x
Yield 2022 -
Sales 2023 614 M - -
Net income 2023 -137 M - -
Net cash position 2023 148 M - -
P/E ratio 2023 -41,2x
Yield 2023 -
Capitalization 5 447 M 5 447 M -
EV / Sales 2022 10,3x
EV / Sales 2023 8,63x
Nbr of Employees 1 239
Free-Float 79,3%
More Financials
Company
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables, and software for analyzing biological systems. Its products include Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Gene Expression, Spatial... 
Read more
More about the company
Ratings of 10x Genomics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about 10X GENOMICS, INC.
01/1910x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February ..
PR
01/09Transcript : 10x Genomics, Inc. Presents at 41st Annual J.P. Morgan Healthcar..
CI
01/05Cornell University : Method precisely locates gene activity and proteins across tissues
AQ
202210x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
2022Cancer researchers question antitrust arguments against Illumina-Grail deal
RE
2022Deutsche Bank Initiates Coverage on 10x Genomics With Buy Rating, $50 Price Target
MT
202210x Genomics : Investor Day Presentation
PU
202210x Genomics Commercially Launches Xenium Platform for In Situ Analysis
PR
202210x Genomics, Inc. Launches Xenium Platform for In Situ Analysis
CI
2022Transcript : 10x Genomics, Inc. - Analyst/Investor Day
CI
2022Jumpcode Genomics Joins 10x Genomics' Compatible Partner Program (CPP)
AQ
2022Sector Update: Health Care Stocks Carried Higher in Market Rally
MT
2022Sector Update: Health Care Stocks Tracking Higher on Thursday
MT
2022Sector Update: Health Care
MT
202210x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Disco..
PR
More news
News in other languages on 10X GENOMICS, INC.
202210x Genomics, Inc. Lance la plateforme Xenium pour l'analyse in situ
2022Mise à jour sectorielle : Les actions du secteur de la santé por..
2022Mise à jour sectorielle : Les actions du secteur de la santé sui..
2022Mise à jour sectorielle : Soins de santé
202210X Genomics, Inc. annonce la disponibilité commerciale de BEAM
More news
Analyst Recommendations on 10X GENOMICS, INC.
More recommendations
ETFs positioned on 10X GENOMICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
CI Bio-Revolution ETF - CAD1.53%0.99%-NC
Xtrackers MSCI Genomic Healthcare Innovatio...0.75%-0.11%-NC
HAN-GINS Indxx Healthcare Megatrend Equal W...0.64%1.99%-NC
BMO MSCI Genomic Innovation Index ETF - CAD0.53%-1.39%-NC
Nomura NEXT FUNDS International Equity MSCI...0.31%-0.34%-World
More ETFs positioned on 10X GENOMICS, INC.
Chart 10X GENOMICS, INC.
Duration : Period :
10x Genomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 10X GENOMICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 47,59 $
Average target price 49,67 $
Spread / Average Target 4,36%
EPS Revisions
Managers and Directors
Serge Saxonov Chief Executive Officer & Director
Benjamin J. Hindson Director
Justin J. McAnear Chief Financial & Accounting Officer
John R. Stuelpnagel Chairman
Michael Schnal-Levin Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
10X GENOMICS, INC.30.60%5 447
BIOMÉRIEUX-4.51%12 003
DIASORIN S.P.A.-8.55%6 915
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.14.18%6 431
AUTOBIO DIAGNOSTICS CO., LTD.7.84%5 719
NATERA, INC.6.87%4 681